Clinical Trial Update: HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED) [Phase 3]

View source ↗

Summary

Phase 3 double-masked trial of SYL1001 for Dry Eye Disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• SYL1001

Snippet

Sponsor: Sylentis, S.A. | Conditions: Dry Eye Disease | Phase 3 | Status: COMPLETED